Parvexon-Injection for ECF-100ml

Description

Parvexon? ? Features & Description

Active Ingredient & Formulation

• Parvaquone 150?mg/mL: A lipophilic naphthoquinone of the hydroxynaphthoquinone family, formulated as a ready-to-use oil-based injectable solution?potent against both piroplasm and schizont stages of Theileria parva.

?Indications

• Primary Use: Treatment of East Coast Fever (ECF) and other Theileriosis in cattle.

• Effective At: Both early-stage infections (clinical signs) and subclinical infections in apparently healthy but Theileria-positive cattle.

Key Benefits

1. Dual-stage efficacy: Targets both schizonts and piroplasms of the parasite?essential for a comprehensive cure.

2. Suitable for all signs: Treats animals showing symptoms and those poised to develop disease.

3. Pack convenience: Available in 50?mL and 100?mL vials?ideal for small or large herds.

4. Clear withdrawal guidelines:

   • Meat & Offal: 28 days

   • Milk: 14 days .

Packaging Options

• 50?mL vial (72 per case)

• 100?mL vial (48 per case)

Dosage & Administration

• Administered intramuscularly at 1?mL per 15?kg body weight (~10?mg/kg).

• Repeat dose after 48 hours, if required.

Special Considerations

• For advanced ECF with pulmonary oedema, the combination product Parvexon Plus (Parvaquone + Frusemide) is available?designed specifically to reduce pulmonary fluid build-up.

• Curing rates from clinical trials:

  • Parvexon alone: 88?100% cure rates in non-edematous cases

  • Parvexon Plus: 93% cure in total, and better in cases with pulmonary oedema

?? Features at a Glance